Yield10 Bioscience, Inc.
US ˙ OTCPK

Introduktion

Denne side giver en omfattende analyse af den kendte insiderhandelshistorie for Nostrand Robert L Van. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Det er ulovligt for insidere at foretage handler i deres virksomheder baseret på specifik, ikke-offentlig information. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4. På trods af disse begrænsninger tyder akademisk forskning på, at insidere - generelt - har en tendens til at klare sig bedre end markedet i deres egne virksomheder.

Gennemsnitlig handelsrentabilitet

Den gennemsnitlige handelsrentabilitet er det gennemsnitlige afkast af alle køb på det åbne marked foretaget af insideren i de sidste tre år. For at beregne dette undersøger vi ethvert åbent marked, uplanlagte køb foretaget af insideren, eksklusive alle handler, der var markeret som en del af en 10b5-1-handelsplan. Vi beregner derefter den gennemsnitlige præstation for disse handler over 3, 6 og 12 måneder, idet vi tager et gennemsnit af hver af disse varigheder for at generere en endelig præstationsmåling for hver handel. Endelig tager vi et gennemsnit af alle præstationsmålingerne for at beregne en præstationsmåling for insideren. Denne liste inkluderer kun insidere, der har foretaget mindst tre handler i de sidste to år.

Hvis denne insiderhandelsrentabilitet er "N/A", så har insideren enten ikke foretaget nogen køb på det åbne marked i de sidste tre år, eller de handler, de har foretaget, er for nye til at beregne en pålidelig præstationsmåling.

Opdateringsfrekvens: Dagligt

Se listen over de mest profitable insiderhandlere.

Virksomheder med rapporterede insider-stillinger

SEC-registreringen viser, at Nostrand Robert L Van har rapporteret besiddelser eller handler i følgende virksomheder:

Sikkerhed Titel Senest indberettede beholdninger
US:SLS / SELLAS Life Sciences Group, Inc. Director 20.400
US:ITCI / Intra-Cellular Therapies, Inc. Director 0
US:YTEN / Yield10 Bioscience, Inc. Director 48.635
Director 0
US:ENUM / Enumeral Biomedical Holdings, Inc. Director 268.121
Sådan fortolkes diagrammerne

Følgende diagrammer viser aktieudviklingen for værdipapirer efter hver åben-marked, ikke-planlagt handel foretaget af Nostrand Robert L Van. Ikke-planlagt handel er handler, der ikke blev foretaget som en del af en 10b5-1-handelsplan. Aktieudviklingen er kortlagt som den kumulative procentvise ændring i aktiekursen. For eksempel, hvis en insiderhandel blev foretaget den 1. januar 2019, vil diagrammet vise den daglige procentvise ændring af værdipapiret til i dag. Hvis aktiekursen skulle gå fra $10 til $15 i løbet af denne tid, ville den kumulative procentvise ændring i aktiekursen være 50%. En prisændring fra 10 USD til 20 USD ville være 100 %, og en ændring i prisen på 10 USD til 5 USD ville være -50 %.

I sidste ende forsøger vi at bestemme, hvor tæt insiderens handler korrelerer med merafkast (positive eller negative) i aktiekursen for at se, om insideren timing deres handler til at drage fordel af insiderinformation. Overvej situationen, hvor en insider gjorde dette. I denne situation ville vi forvente enten (a) positive afkast efter køb eller (b) negative afkast efter salg. I tilfælde af (a) vil KØB-diagrammet vise en række opadskrånende kurver, der indikerer positive afkast efter hver købstransaktion. I tilfælde af (b) vil SALE-diagrammet vise en række nedadgående kurver, der indikerer negative afkast efter hver salgstransaktion.

Dette alene er dog ikke nok til at drage konklusioner. Hvis for eksempel aktiekursen i selskabet var i en ikke-cyklisk stigning over mange år, så ville vi forvente, at alle efterkøbsgrundene var opadgående. Ligeledes ville ikke-cykliske fald over mange år resultere i nedadgående post-trade plots. Ingen af disse diagrammer tyder på insiderhandel.

Den stærkeste indikator ville være en situation, hvor aktiekursen var ekstremt cyklisk, og der var både positive signaler i KØB-diagrammet og negative plots på SALG-diagrammet. Denne situation ville i høj grad tyde på en insider, der havde timing af handler til deres økonomiske fordel.

Insiderkøb YTENQ / Yield10 Bioscience, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i YTENQ / Yield10 Bioscience, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
2012-11-30 MBLX VAN NOSTRAND ROBERT L 20.000 1,0700 20.000 1,0700 21.400 730

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

YTENQ / Yield10 Bioscience, Inc. Insider Trades
Insidersalg YTENQ / Yield10 Bioscience, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i YTENQ / Yield10 Bioscience, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

YTENQ / Yield10 Bioscience, Inc. Insider Trades
Insiderhandelshistorie

Denne tabel viser den komplette liste over insiderhandler foretaget af Nostrand Robert L Van som oplyst til Securities Exchange Commission (SEC).

Fil dato Transdato Form Ticker Sikkerhed Kode 10b5-1 Aktier Resterende aktier Procent
Lave om
Del
Pris
Tran
Værdi
Tilbage
Værdi
2025-06-13 2025-06-12 4 SLS SELLAS Life Sciences Group, Inc.
Common Stock
P - Purchase 10.000 20.400 96,15 1,48 14.800 30.192
2025-04-02 2025-04-02 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
D - Sale to Issuer -11.340 0 -100,00 132,00 -1.496.880
2025-01-14 2025-01-10 4 SLS SELLAS Life Sciences Group, Inc.
Common Stock
A - Award 12.500 22.900 120,19
2024-07-02 2024-06-28 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
A - Award 83 11.340 0,74 68,49 5.685 776.677
2024-06-25 2024-06-23 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
M - Exercise 1.567 11.257 16,17
2024-06-21 2024-06-18 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
S - Sale X -11.109 9.690 -53,41 76,07 -845.062 737.118
2024-06-21 2024-06-18 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
S - Sale X -8.891 20.799 -29,95 75,71 -673.138 1.574.692
2024-06-21 2024-06-18 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
M - Exercise 20.000 29.690 206,40 16,86 337.200 500.573
2024-04-02 2024-03-31 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
A - Award 79 9.690 0,82 69,20 5.467 670.548
2024-04-01 2024-03-28 4 YTEN YIELD10 BIOSCIENCE, INC.
Common Stock
A - Award 11.924 48.635 32,48
2024-02-28 2024-02-27 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
S - Sale -10.349 9.611 -51,85 73,14 -756.926 702.949
2024-02-28 2024-02-27 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
S - Sale -9.651 19.960 -32,59 72,71 -701.724 1.451.292
2024-02-28 2024-02-27 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
M - Exercise 20.000 29.611 208,09 18,56 371.200 549.580
2024-01-25 2024-01-22 4 SLS SELLAS Life Sciences Group, Inc.
Common Stock
A - Award 6.000 10.400 136,36
2024-01-03 2023-12-29 4 YTEN YIELD10 BIOSCIENCE, INC.
Common Stock
A - Award 18.879 36.711 105,87
2024-01-03 2023-12-31 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
A - Award 76 9.611 0,80 71,62 5.443 688.340
2023-10-02 2023-09-29 4 YTEN YIELD10 BIOSCIENCE, INC.
Common Stock
A - Award 13.868 17.832 349,85
2023-10-02 2023-09-30 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
A - Award 105 9.535 1,11 52,09 5.469 496.678
2023-07-05 2023-06-30 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
A - Award 85 9.430 0,91 63,32 5.382 597.108
2023-07-05 2023-06-30 4 YTEN YIELD10 BIOSCIENCE, INC.
Common Stock
A - Award 2.040 3.964 106,03
2023-04-19 2023-04-17 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
S - Sale X -10.000 9.345 -51,69 63,00 -630.000 588.735
2023-04-19 2023-04-17 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
M - Exercise 10.000 19.345 107,01 13,05 130.500 252.452
2023-04-04 2023-03-31 4 YTEN YIELD10 BIOSCIENCE, INC.
Common Stock
A - Award 1.642 1.924 582,27
2023-04-04 2023-03-31 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
A - Award 95 9.345 1,03 54,15 5.144 506.032
2023-02-03 2023-02-02 4 SLS SELLAS Life Sciences Group, Inc.
Common Stock
A - Award 2.500 4.400 131,58
2023-01-03 2022-12-30 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
A - Award 97 9.250 1,06 52,92 5.133 489.510
2022-10-05 2022-09-30 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
A - Award 110 9.153 1,22 46,53 5.118 425.889
2022-08-12 2022-08-11 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
S - Sale -1.500 9.043 -14,23 56,80 -85.200 513.642
2022-08-12 2022-08-11 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
S - Sale -28.500 10.543 -73,00 57,15 -1.628.775 602.532
2022-08-12 2022-08-11 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
M - Exercise 10.000 39.043 34,43 13,05 130.500 509.511
2022-08-12 2022-08-11 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
M - Exercise 20.000 29.043 221,17 12,45 249.000 361.585
2022-07-05 2022-06-30 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
A - Award 108 9.043 1,21 57,08 6.165 516.174
2022-05-26 2022-05-25 4 YTEN YIELD10 BIOSCIENCE, INC.
Stock Option (right to buy)
A - Award 5.000 5.000
2022-04-04 2022-03-31 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
A - Award 126 8.935 1,43 61,19 7.710 546.733
2022-04-04 2022-03-31 4 YTEN YIELD10 BIOSCIENCE, INC.
Stock Option (right to buy)
A - Award 908 908 4,99 4.531 4.531
2022-02-01 2022-01-31 4 SLS SELLAS Life Sciences Group, Inc.
Stock Option (Right to Buy)
A - Award 7.125 7.125
2022-02-01 2022-01-31 4 SLS SELLAS Life Sciences Group, Inc.
Common Stock
A - Award 1.900 1.900
2022-01-04 2021-12-31 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
A - Award 148 8.809 1,71 52,34 7.746 461.063
2022-01-03 2021-12-31 4 YTEN YIELD10 BIOSCIENCE, INC.
Stock Option (right to buy)
A - Award 976 976 4,64 4.529 4.529
2021-10-04 2021-09-30 4 YTEN YIELD10 BIOSCIENCE, INC.
Stock Option (right to buy)
A - Award 801 801 5,66 4.534 4.534
2021-10-04 2021-09-30 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
A - Award 215 8.661 2,55 37,28 8.015 322.882
2021-07-02 2021-06-30 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
A - Award 173 8.446 2,09 40,82 7.062 344.766
2021-07-01 2021-06-30 4 YTEN YIELD10 BIOSCIENCE, INC.
Stock Option (right to buy)
A - Award 562 562 8,06 4.530 4.530
2021-06-22 2021-06-21 4 ITCI Intra-Cellular Therapies, Inc.
Stock Option (right to buy)
A - Award 20.000 20.000
2021-05-26 2021-05-24 4 YTEN YIELD10 BIOSCIENCE, INC.
Stock Option (right to buy)
A - Award 5.000 5.000
2021-04-02 2021-03-31 4 YTEN YIELD10 BIOSCIENCE, INC.
Stock Option (right to buy)
A - Award 383 383 11,84 4.535 4.535
2021-04-02 2021-03-31 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
A - Award 208 8.273 2,58 33,93 7.057 280.703
2021-03-08 2021-03-04 4 SLS SELLAS Life Sciences Group, Inc.
Stock Option (Right to Buy)
A - Award 7.500 7.500
2021-01-05 2020-12-31 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
A - Award 222 8.065 2,83 31,80 7.060 256.467
2021-01-04 2020-12-31 4 YTEN YIELD10 BIOSCIENCE, INC.
Stock Option (right to buy)
A - Award 818 818 5,54 4.532 4.532
2020-10-02 2020-09-30 4 YTEN YIELD10 BIOSCIENCE, INC.
Stock Option (right to buy)
A - Award 624 624 7,26 4.530 4.530
2020-10-02 2020-09-30 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
A - Award 276 7.843 3,65 25,66 7.082 201.251
2020-07-02 2020-06-30 4 YTEN YIELD10 BIOSCIENCE, INC.
Stock Option (right to buy)
A - Award 777 777 5,84 4.538 4.538
2020-07-02 2020-06-30 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
A - Award 275 7.567 3,77 25,67 7.059 194.245
2020-05-29 2020-05-28 4 YTEN YIELD10 BIOSCIENCE, INC.
Stock Option (right to buy)
A - Award 5.000 5.000
2020-05-28 2020-05-27 4 ITCI Intra-Cellular Therapies, Inc.
Stock Option (right to buy)
A - Award 20.000 20.000
2020-04-02 2020-03-31 4 YTEN YIELD10 BIOSCIENCE, INC.
Stock Option (right to buy)
A - Award 1.294 1.294 3,50 4.529 4.529
2020-04-02 2020-03-31 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
A - Award 460 7.292 6,73 15,37 7.070 112.078
2020-03-16 2020-03-12 4 SLS SELLAS Life Sciences Group, Inc.
Stock Option (Right to Buy)
A - Award 6.500 6.500
2020-01-29 2020-01-28 4 ACHN ACHILLION PHARMACEUTICALS INC
Stock Options (Right to buy)
D - Sale to Issuer -42.000 0 -100,00
2020-01-29 2020-01-28 4 ACHN ACHILLION PHARMACEUTICALS INC
Stock Options (Right to buy)
D - Sale to Issuer -30.000 0 -100,00
2020-01-29 2020-01-28 4 ACHN ACHILLION PHARMACEUTICALS INC
Stock Options (Right to buy)
D - Sale to Issuer -30.000 0 -100,00
2020-01-29 2020-01-28 4 ACHN ACHILLION PHARMACEUTICALS INC
Stock Options (Right to buy)
D - Sale to Issuer -25.000 0 -100,00
2020-01-29 2020-01-28 4 ACHN ACHILLION PHARMACEUTICALS INC
Stock Options (Right to buy)
D - Sale to Issuer -50.000 0 -100,00
2020-01-29 2020-01-28 4 ACHN ACHILLION PHARMACEUTICALS INC
Stock Options (Right to buy)
D - Sale to Issuer -30.000 0 -100,00
2020-01-29 2020-01-28 4 ACHN ACHILLION PHARMACEUTICALS INC
Stock Options (Right to buy)
D - Sale to Issuer -20.000 0 -100,00
2020-01-29 2020-01-28 4 ACHN ACHILLION PHARMACEUTICALS INC
Common Stock
D - Sale to Issuer -40.000 0 -100,00 6,30 -252.000
2020-01-03 2019-12-31 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
A - Award 170 6.832 2,55 34,31 5.833 234.406
2019-12-19 2019-12-18 4 ACHN ACHILLION PHARMACEUTICALS INC
Stock Option (Right to Buy)
M - Exercise -20.000 0 -100,00
2019-12-19 2019-12-18 4 ACHN ACHILLION PHARMACEUTICALS INC
Common Stock
M - Exercise 20.000 40.000 100,00 3,28 65.600 131.200
2019-10-02 2019-09-30 4 YTEN YIELD10 BIOSCIENCE, INC.
Stock Option (right to buy)
A - Award 9.845 9.845 0,46 4.529 4.529
2019-10-02 2019-09-30 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
A - Award 780 6.662 13,26 7,47 5.827 49.765
2019-07-02 2019-06-28 4 YTEN YIELD10 BIOSCIENCE, INC.
Stock Option (right to buy)
A - Award 5.096 5.096 0,89 4.535 4.535
2019-07-02 2019-06-28 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
A - Award 449 5.882 8,26 12,98 5.828 76.348
2019-06-26 2019-06-25 4 ITCI Intra-Cellular Therapies, Inc.
Stock Option (right to buy)
A - Award 20.000 20.000
2019-05-23 2019-05-22 4 YTEN YIELD10 BIOSCIENCE, INC.
Stock Option (right to buy)
A - Award 10.000 10.000
2019-04-02 2019-03-29 4 YTEN YIELD10 BIOSCIENCE, INC.
Stock Option (right to buy)
A - Award 4.321 4.321 1,05 4.537 4.537
2019-04-02 2019-03-31 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
A - Award 478 5.433 9,65 12,18 5.822 66.174
2019-03-18 2019-03-14 4 SLS SELLAS Life Sciences Group, Inc.
Stock Option (Right to Buy)
A - Award 25.000 25.000
2019-01-25 2019-01-23 4 ACHN ACHILLION PHARMACEUTICALS INC
Stock Option (Right to buy)
A - Award 42.000 42.000
2019-01-03 2018-12-31 4 YTEN YIELD10 BIOSCIENCE, INC.
Stock Option (right to buy)
A - Award 5.924 5.924 0,76 4.502 4.502
2019-01-03 2018-12-31 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
A - Award 512 4.955 11,52 11,39 5.832 56.437
2018-12-18 2018-12-14 4 ACHN ACHILLION PHARMACEUTICALS INC
Employee Stock Option
M - Exercise -20.000 0 -100,00
2018-12-18 2018-12-14 4 ACHN ACHILLION PHARMACEUTICALS INC
Common Stock
M - Exercise 20.000 20.000 1,05 21.000 21.000
2018-10-02 2018-09-28 4 YTEN YIELD10 BIOSCIENCE, INC.
Stock Option (right to buy)
A - Award 3.396 3.396 1,33 4.517 4.517
2018-10-02 2018-09-30 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
A - Award 268 4.443 6,42 21,70 5.816 96.413
2018-07-03 2018-06-29 4 YTEN YIELD10 BIOSCIENCE, INC.
Stock Option (right to buy)
A - Award 3.464 3.464 1,31 4.538 4.538
2018-07-03 2018-06-29 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
A - Award 282 4.175 7,24 17,67 4.983 73.772
2018-06-20 2018-06-18 4 ITCI Intra-Cellular Therapies, Inc.
Stock Option (right to buy)
A - Award 20.000 20.000
2018-06-13 2018-06-12 4 SLS SELLAS Life Sciences Group, Inc.
Stock Option (Right to Buy)
A - Award 5.500 5.500
2018-05-25 2018-05-23 4 YTEN YIELD10 BIOSCIENCE, INC.
Stock Option (right to buy)
A - Award 10.000 10.000
2018-04-03 2018-03-30 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
A - Award 237 3.893 6,48 21,05 4.989 81.948
2018-04-02 2018-03-29 4 YTEN YIELD10 BIOSCIENCE, INC.
Stock Option (right to buy)
A - Award 2.860 2.860 1,58 4.519 4.519
2018-03-15 2018-03-13 4 SLS SELLAS Life Sciences Group, Inc.
Stock Option (Right to Buy)
A - Award 11.000 11.000
2018-02-13 2018-02-09 4 ACHN ACHILLION PHARMACEUTICALS INC
Employee Stock Option
A - Award 30.000 30.000
2018-01-03 2017-12-29 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
P - Purchase 345 3.656 10,42 14,48 4.996 52.939
2018-01-03 2017-12-29 4 YTEN YIELD10 BIOSCIENCE, INC.
Stock Option (right to buy)
A - Award 13.003 13.003 1,39 18.074 18.074
2018-01-03 2017-12-29 4/A ITCI Intra-Cellular Therapies, Inc.
Common Stock
A - Award 345 3.656 10,42 14,48 4.996 52.939
2017-12-29 3 SLS SELLAS Life Sciences Group, Inc.
Common Stock
0
2017-11-30 2017-11-28 4 YTEN YIELD10 BIOSCIENCE, INC.
Stock Option (right to buy)
A - Award 10.165 10.165
2017-10-03 2017-09-29 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
A - Award 316 3.311 10,55
2017-07-05 2017-06-30 4 YTEN YIELD10 BIOSCIENCE, INC.
Common Stock
A - Award 3.519 11.293 45,27
2017-07-05 2017-06-30 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
A - Award 402 2.995 15,50
2017-06-29 2017-06-27 4 ITCI Intra-Cellular Therapies, Inc.
Stock Option (right to buy)
A - Award 20.000 20.000
2017-05-26 2017-05-24 4 YTEN YIELD10 BIOSCIENCE, INC.
Stock Option (right to buy)
A - Award 25.000 25.000
2017-05-26 2017-05-24 4 YTEN YIELD10 BIOSCIENCE, INC.
Common Stock
A - Award 43.155 46.488 1.294,78
2017-04-04 2017-03-31 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
A - Award 307 2.593 13,43
2017-01-19 2017-01-19 4 ACHN ACHILLION PHARMACEUTICALS INC
Employee Stock Option
A - Award 30.000 30.000
2017-01-05 2017-01-03 4 ENUM Enumeral Biomedical Holdings, Inc.
Common Stock
A - Award 66.666 268.121 33,09
2017-01-03 2016-12-30 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
A - Award 331 2.286 16,93
2016-12-13 2016-12-09 4 ENUM Enumeral Biomedical Holdings, Inc.
Common Stock Purchase Warrant
M - Exercise -156.000 0 -100,00 0,12 -19.500
2016-12-13 2016-12-09 4 ENUM Enumeral Biomedical Holdings, Inc.
Common Stock Purchase Warrant
J - Other 156.000 156.000 0,12 19.500 19.500
2016-12-13 2016-12-09 4 ENUM Enumeral Biomedical Holdings, Inc.
Common Stock Purchase Warrant
P - Purchase 39.000 39.000 0,08 3.120 3.120
2016-12-13 2016-12-09 4 ENUM Enumeral Biomedical Holdings, Inc.
Common Stock
M - Exercise 156.000 201.455 343,20 0,12 19.500 25.182
2016-10-04 2016-09-30 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
A - Award 328 1.955 20,16
2016-07-05 2016-06-30 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
A - Award 128 1.627 8,54
2016-06-15 2016-06-14 4 ITCI Intra-Cellular Therapies, Inc.
Stock Option (right to buy)
A - Award 20.000 20.000
2016-04-04 2016-03-31 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
A - Award 134 1.499 9,82
2016-01-27 2016-01-25 4 ACHN ACHILLION PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 30.000 30.000
2016-01-06 2016-01-04 4 ENUM Enumeral Biomedical Holdings, Inc.
Common Stock
A - Award 45.455 45.455
2016-01-05 2015-12-31 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
A - Award 69 1.365 5,32 53,79 3.712 73.423
2015-10-02 2015-09-30 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
A - Award 93 1.296 7,73
2015-09-24 2015-09-22 4 ENUM Enumeral Biomedical Holdings, Inc.
Common Stock Option (Right to Buy)
A - Award 76.000 76.000
2015-09-14 2015-09-10 4 MBLX METABOLIX, INC.
Common Stock
A - Award 31.250 31.250
2015-07-02 2015-06-30 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
A - Award 117 1.203 10,77
2015-06-22 2015-06-16 4 ITCI Intra-Cellular Therapies, Inc.
Stock Option (right to buy)
A - Award 20.000 20.000
2015-04-03 3 ENUM Enumeral Biomedical Holdings, Inc.
Common Stock
0
2015-04-02 2015-03-31 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
A - Award 157 1.086 16,90
2015-01-05 2014-12-31 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
A - Award 212 929 29,57
2014-12-04 2014-12-02 4 ACHN ACHILLION PHARMACEUTICALS INC
Common Stock (Right to Buy)
A - Award 25.000 25.000
2014-10-02 2014-09-30 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
A - Award 273 717 61,49
2014-07-02 2014-06-30 4 ITCI Intra-Cellular Therapies, Inc.
Stock Option (right to buy)
A - Award 20.000 20.000
2014-07-02 2014-06-30 4 ITCI Intra-Cellular Therapies, Inc.
Common Stock
A - Award 444 444
2014-05-29 2014-05-28 4 MBLX METABOLIX, INC.
Stock Option
A - Award 25.000 25.000
2014-03-24 2014-03-21 4 ITCI Intra-Cellular Therapies, Inc.
Stock Option (right to buy)
A - Award 20.000 20.000
2014-03-13 2014-01-02 4/A MBLX METABOLIX, INC.
Stock Option (right to buy)
A - Award 50.000 50.000
2014-01-06 2014-01-02 4 MBLX METABOLIX, INC.
Stock Option (right to buy)
A - Award 50.000 50.000
2013-12-19 2013-12-17 4 ACHN ACHILLION PHARMACEUTICALS INC
Common Stock (Right to Buy)
A - Award 25.000 25.000
2013-06-10 2013-06-06 4 MBLX METABOLIX, INC.
Stock Option
A - Award 10.000 10.000
2012-12-20 2012-12-18 4 ACHN ACHILLION PHARMACEUTICALS INC
Common Stock (Right to Buy)
A - Award 20.000 20.000
2012-12-04 2012-11-30 4 MBLX METABOLIX, INC.
Common Stock
P - Purchase 20.000 20.000 1,07 21.400 21.400
2012-06-11 2012-06-07 4 MBLX METABOLIX, INC.
Stock Option (right to buy)
A - Award 10.000 10.000
P
Åbent marked eller privat køb af ikke-afledte eller afledte værdipapirer
S
Åbent marked eller privat salg af ikke-afledte eller afledte værdipapirer
A
Tildeling, tildeling eller anden erhvervelse af værdipapirer fra virksomheden (såsom en option)
C
Konvertering af derivat
D
Salg eller overførsel af værdipapirer tilbage til virksomheden
F
Betaling af udnyttelseskurs eller skatteforpligtelse ved brug af en del af værdipapirer modtaget fra selskabet
G
Gave af værdipapirer af eller til insideren
K
Aktieswaps og lignende sikringstransaktioner
M
Udnyttelse eller konvertering af afledt værdipapir modtaget fra virksomheden (såsom en option)
V
En transaktion rapporteret frivilligt på formular 4
J
Andet (ledsaget af en fodnote, der beskriver transaktionen)